Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease?
about
Decreased vascular lesion formation in mice with inducible endothelial-specific expression of protein kinase AktACE inhibition and atherogenesis.The russert impact: a golden opportunity to promote primary coronary prevention.Embolic protection devices.Glycoprotein IIb/IIIa receptor inhibitors in percutaneous coronary intervention and acute coronary syndrome.Impact of angiotensin converting enzyme inhibition on post-coronary artery bypass interleukin 6 release.Prospective evaluation of the effect of an angiotensin I converting enzyme gene polymorphism on the long term risk of major adverse cardiac events after percutaneous coronary intervention.Multifactorial approach to the primary and secondary prevention of atherosclerosis.Technical aspects of diastology: why mitral inflow and tissue Doppler imaging are the preferred parameters?Bayesian meta-analysis of tissue angiotensin-converting enzyme inhibitors for reduction of adverse cardiovascular events in patients with diabetes mellitus and preserved left ventricular function.The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection.Hypertension and antihypertensive therapy in Hispanics and Mexican Americans living in the United States.Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers Are Associated With Improved Outcome but Do Not Prevent New-Onset Atrial Fibrillation After Acute Myocardial Infarction.Comparison of angiotensin II type 1-receptor blockers to regress pressure overload-induced cardiac hypertrophy in mice.Drug-eluting stents for the prevention of restenosis: in quest for the Holy Grail.Cost effectiveness of ramipril in patients at high risk for cardiovascular events : economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the Statutory Health Insurance perspective.Treatment of essential arterial hypertension with enalapril does not result in normalization of endothelial dysfunction of the conduit arteries.ACE inhibition for severe bronchopulmonary dysplasia - an approach based on physiology
P2860
Q34331352-6ED3EEEE-6C10-4E4F-8302-860077E993C9Q34652136-E476A383-78A1-4949-BD16-3983E2B2495AQ34986590-FB71C2A2-220F-42CE-A9C9-10F7214239E8Q35022895-7AEBCBF6-3E08-4FFF-844B-125750283CD1Q35139249-13D48B96-18FA-469F-B0BD-E113D12D6944Q35579754-550ED85B-76E2-4BEB-B1EC-E0120555AFA5Q35580995-266B4B3E-A833-4E23-8C14-7E4B751F2165Q35857910-9F274456-1820-4731-AF53-7EDA253CBC32Q36460961-7CAF5353-C1D1-413F-BA6C-B416FF79B790Q37104532-D7FE0532-9FD2-4E74-B321-6B1A9D55CA49Q37169716-444FB1B6-F00C-4595-9832-F403A4493362Q37959151-57D20B22-31DE-4E47-B3FB-FD735A927B38Q41104013-4BD7CFB9-26C2-4340-B552-760E5D2467AEQ42859674-6EE41A51-8490-4F89-9136-B499B426ED4AQ43900398-87E3489C-F965-47B9-9576-45F392F6325BQ45079359-C7578280-50D8-457E-8137-BD21A22E4318Q46976518-2D420367-9D2A-4766-969E-7627DA7D5760Q58763326-83B4B062-FB33-41B8-9ED5-BB2EE1FBBBD3
P2860
Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease?
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Should an angiotensin-converti ...... with atherosclerotic disease?
@ast
Should an angiotensin-converti ...... with atherosclerotic disease?
@en
type
label
Should an angiotensin-converti ...... with atherosclerotic disease?
@ast
Should an angiotensin-converti ...... with atherosclerotic disease?
@en
prefLabel
Should an angiotensin-converti ...... with atherosclerotic disease?
@ast
Should an angiotensin-converti ...... with atherosclerotic disease?
@en
P2093
P1476
Should an angiotensin-converti ...... with atherosclerotic disease?
@en
P2093
P356
10.1016/S0735-1097(00)01044-5
P407
P577
2001-01-01T00:00:00Z